New York State Common Retirement Fund trimmed its holdings in shares of NewLink Genetics Corp (NASDAQ:NLNK) by 18.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,800 shares of the biotechnology company’s stock after selling 5,091 shares during the period. New York State Common Retirement Fund owned about 0.07% of NewLink Genetics worth $160,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. UBS Asset Management Americas Inc. bought a new position in NewLink Genetics during the 1st quarter worth about $297,000. State of Wisconsin Investment Board purchased a new stake in shares of NewLink Genetics during the second quarter valued at about $125,000. Trexquant Investment LP lifted its position in shares of NewLink Genetics by 39.1% during the second quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 5,097 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of NewLink Genetics during the second quarter valued at about $165,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in shares of NewLink Genetics during the first quarter valued at about $555,000. Institutional investors own 46.09% of the company’s stock.

Several analysts have commented on NLNK shares. Robert W. Baird raised shares of NewLink Genetics from a “neutral” rating to an “outperform” rating and increased their price target for the company from $8.00 to $22.00 in a research report on Friday, September 8th. ValuEngine lowered shares of NewLink Genetics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Stifel Nicolaus increased their price target on shares of NewLink Genetics from $14.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Bank of America Corporation started coverage on shares of NewLink Genetics in a research report on Friday, October 13th. They set a “buy” rating and a $22.00 price target for the company. Finally, Jefferies Group LLC decreased their price target on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. NewLink Genetics presently has an average rating of “Buy” and an average price target of $23.43.

NewLink Genetics Corp (NLNK) opened at $8.74 on Monday. NewLink Genetics Corp has a 1 year low of $5.90 and a 1 year high of $25.17.

In related news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the firm’s stock in a transaction that occurred on Friday, October 6th. The stock was purchased at an average cost of $10.25 per share, with a total value of $7,999,991.75. Following the transaction, the insider now directly owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 13.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “New York State Common Retirement Fund Sells 5,091 Shares of NewLink Genetics Corp (NLNK)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/27/new-york-state-common-retirement-fund-sells-5091-shares-of-newlink-genetics-corp-nlnk.html.

NewLink Genetics Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corp (NASDAQ:NLNK).

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Stock Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related stocks with our FREE daily email newsletter.